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Behavioral lifestyle factors are associated with cardiometabolic disease and obesity, which are risk
factors for coronavirus disease 2019 (COVID-19). We aimed to investigate whether physical activity,
and the timing and balance of physical activity and sleep/rest, were associated with SARS-CoV-2
positivity and COVID-19 severity. Data from 91,248 UK Biobank participants with accelerometer
data and complete covariate and linked COVID-19 data to July 19, 2020, were included. The risk of
SARS-CoV-2 positivity and COVID-19 severitydin relation to overall physical activity, moderate-to-
vigorous physical activity (MVPA), balance between activity and sleep/rest, and variability in timing of
sleep/restdwas assessed with adjusted logistic regression. Of 207 individuals with a positive test
result, 124 were classified as having a severe infection. Overall physical activity and MVPA were not
associated with severe COVID-19, whereas a poor balance between activity and sleep/rest was (odds
ratio [OR] per standard deviation: 0.71; 95% confidence interval [CI], 0.62 to 0.81]). This finding was
related to higher daytime activity being associated with lower risk (OR, 0.75; 95% CI, 0.61 to 0.93) but
higher movement during sleep/rest being associated with higher risk (OR, 1.26; 95% CI, 1.12 to 1.42)
of severe infection. Greater variability in timing of sleep/rest was also associated with increased risk
(OR, 1.21; 95% CI, 1.08 to 1.35). Results for testing positive were broadly consistent. In conclusion,
these results highlight the importance of not just physical activity, but also quality sleep/rest and
regular sleep/rest patterns, on risk of COVID-19. Our findings indicate the risk of COVID-19 was
consistently approximately 1.2-fold greater per approximately 40-minute increase in variability in
timing of proxy measures of sleep, indicative of irregular sleeping patterns.
ª 2020 Mayo Foundation for Medical Education and Research n Mayo Clin Proc. 2021;96(1):156-164T here is evidence that the risk of coro-navirus disease 2019 (COVID-19) ishigher in people with cardiometabolic
diseases.1 Recent research also suggests that
the risk is associated with lifestyle-related fac-
tors, including obesity2 and self-reported slow
walking pace,3 a marker of physical fitness.
There has been limited attention to the
risk of COVID-19 and behavioral lifestyle fac-
tors. Low levels of physical activity are
known to be associated with increased risk
of cardiometabolic disease, obesity, and lower
fitness.4 Furthermore, evidence suggests that
irregular sleep timing and increasedMayo Clin Proc. n January 202
www.mayoclinicproceedings.org nvariability in sleep duration are detrimentally
associated with cardiovascular disease risk
and markers of cardiometabolic health.5
This evidence also suggests that a balance be-
tween active behaviors and quality sleep/rest
across the 24-hour day is important for cardi-
ometabolic health. We hypothesize that these
behavioral factors could similarly influence
the risk of COVID-19.
Our aimwas to investigate whether device-
measured physical activitydthe balance be-
tween activity during waking hours and the
main sleep/rest period during the daydand
the timing of the main sleep/rest and activity1;96(1):156-164 n https://doi.org/10.1016/j.mayocp.2020.10.032
ª 2020 Mayo Foundation for Medical Education and Research
ASSOCIATION OF PHYSICAL ACTIVITY AND REST/SLEEP WITH COVID-19periods are associated with the risk of testing
positive for SARS-CoV-2 and developing severe
COVID-19.
MATERIALS AND METHODS
We used data from UK Biobank (application
36371), a prospective cohort of >500,000
adults age 40-69 years.6 Assessments were
conducted between March 2006 and July
2010with data on 24-hourmovement patterns
from Axivity AX3 wrist-worn accelerometers
(Axivity, Newcastle, UK) in >100,000 adults
gathered between June 2013 and December
2015.7 UK Biobank data are linked to national
SARS-CoV-2 laboratory test data through Pub-
lic Health England’s Second Generation Sur-
veillance System; data were available from
March 16, 2020, to July 19, 2020, and included
specimenorigin (hospital inpatient vs other): a
positive test result for SARS-CoV-2with hospi-
talization was considered as evidence of a se-
vere infection, in line with guidance for this
dataset.8 Two SARS-CoV-2 outcomes were
used: (1) severe infection with SARS-CoV-2
and (2) positive test result for SARS-CoV-2.
Analyses were restricted to English cen-
ters, individuals with known sleep disorders
(identified with ICD-10 code G47 in UK Bio-
bank), and those who died before March 16,
2020, were excluded. Participant characteris-
tics, including body mass index (BMI), sex,
ethnicity, and self-reported sleep duration
were collected at the baseline assessment.
For each participant, accelerometer data
(5-second epoch time series) were extracted
from UK Biobank7 and converted to
R-format for processing and analysis with
GGIR (version 1.11-0; http://cran.r-project.
org).9 Participants were excluded if they
failed calibration (including those not cali-
brated on their own data), had fewer than
3 days of valid wear (defined as >16 hours
per day), or wear data were not present for
each 15-minute period of the 24-hours cycle.
Accelerometer outcomes (Table 1) were
averaged across valid days and divided into
three categories: standard physical activity
outcomes, the balance between activity level
and sleep/rest, and the variability in timing of
activity and sleep/rest.Mayo Clin Proc. n January 2021;96(1):156-164 n https://doi.org/10
www.mayoclinicproceedings.orgStatistical Analysis
Logistic regression was used to assess associ-
ations of a severe infection with SARS-CoV-2
(N ¼ 124) with no test or a negative test
result (whole cohort, N ¼ 91,041) as
comparator (model 1) and a positive test
result (N ¼ 207) with a negative result
(N ¼ 2009) as comparator (model 2).
For model 1, participants who tested
positive for COVID-19 but were not classi-
fied as severe (ie, they tested positive in the
community; N ¼ 83) were excluded because
it is possible that these individuals went on
to develop severe COVID-19 but were not
retested on hospital admission. Model 1
can be interpreted as the overall population
level risk of being admitted to hospital
with COVID-19 during the linkage period
within UK Biobank. This population level
method of assessing risk is commonly re-
ported within COVID-19 risk factor
research, and it is of value here as it enables
comparison to the literature in terms of how
the risk factors assessed compare with other
commonly reported risk factors (eg,
obesity).3,11
Model 2 relates specifically to the tested
population, and it can be interpreted as the
risk of a positive test in anyone within UK
Biobank who has been tested for COVID-19.
The physical activity and rest variables
listed in Table 1 were used as independent var-
iables. These variables were standardized
before entry into the models and the odds ra-
tios (ORs) per standard deviation (SD) were
reported for ease of comparison across
variables.
In model 2, regressions were adjusted for
the following potential confounders selected
on current clinical knowledge: age on March
16, 2020; sex; ethnicity; Townsend Depriva-
tion Index; number of people in household;
fruit, vegetable, and red meat consumption;
smoking status; alcohol intake; number of
self-reported cancers and non-cancer ill-
nesses; and number of treatments or medica-
tions taken. The model for severity of
infection (model 1) was adjusted for key de-
mographic variables only (age, sex, and
ethnicity) because of the smaller number of.1016/j.mayocp.2020.10.032 157
TABLE 1. Accelerometer Outcome Variables for Physical Activity and Sleep/Resta
Outcome Unit Abbreviation Interpretation
Physical activity
1 Average acceleration over the 24-hour day mg Overall physical activity Proxy for total physical activity
2 Moderate-to-vigorous physical activity in
1-min boutsb
min MVPA Purposeful activity (e.g. walking) accumulated
in 1-min bouts
Activity and sleep/rest
3 Average acceleration over most active
continuous 16 h
mg Activity during waking hours Overall intensity of movement during the most
active 16 h of the day as a proxy for waking
hours. Greater values present a higher level
of physical activity within this window.
4 Average acceleration over least active
continuous 8 hc
mg Movement during sleep/rest Overall intensity of movement during the least
active 8 h of the day sleep/rest as a proxy
for the sleep window (main rest period).
Lower values represent a more restful
window of recovery.
5 The intensity of the most active 16 h
expressed as % of average acceleration
over the 24-h day
% Balance between activity and sleep/rest A proxy for the balance between activity and
rest/sleep in a 24-h day. A value of 100%
would mean no distinction between activity
and sleep/rest (ie, no drop in movement
levels during the main sleep/rest period). As
the value gets closer to 150% it indicates an
increasingly distinct activity/rest cycle with
two thirds of the day active and one third
resting.
Variability in timing of activity and sleep/rest
6 Variability (SD) in the start time of the most
active continuous 16 h
min Variability in timing of activity Proxy for variability in time of sleep offset
(wake)
7 Variability (SD) in the start time of the least
active continuous 8 hb
min Variability in timing of sleep/rest Proxy for variability in time of sleep onset
8 Variability (SD) in the midpoint of the time
difference between the start of the most
active continuous 16 h and least active
continuous 8 hc
min Variability in sleep/rest midpoint Proxy for variability in mid-sleep time
aMVPA ¼ moderate-to-vigorous physical activity.
bAccelerometer cut-point for classification of MVPA ¼ 100 mg.10
cTo allow for differences in the duration of sleep, we conducted sensitivity analyses assessing the effects of the average acceleration and timing of the least active 6 h rather
than 8 h.
MAYO CLINIC PROCEEDINGS
158outcome events. The activity during waking
hours (3, Table 1) and amount of movement
during sleep/rest (4, Table 1) were also
mutually adjusted for one another and for
sleep duration. When assessing the balance
between activity and sleep/rest (5, Table 1),
and the variability in timing of activity and
sleep/rest (6-8, Table 1), sleep duration was
added to the models. Finally, when assessing
the variability in timing of activity and sleep/
rest (6-8, Table 1) overall activity was also
added to the models.Mayo Clin Proc. n January 202Sensitivity Analyses
1. To allow for differences in sleep duration,
we conducted analyses with the average
acceleration and timing of the least active
6 hours rather than 8 hours.
2. Assuming individuals testing positive in
the community to be non-severe, we
added them to the comparator group for
severe infection with SARS-CoV-2 (severe
infection N ¼ 124; comparator group N ¼
91,124).1;96(1):156-164 n https://doi.org/10.1016/j.mayocp.2020.10.032
www.mayoclinicproceedings.org
TABLE 2. Characteristics of UK Biobank Participants by COVID-19 Positive and Severitya
Variable
Severity of infection (in UK Biobank), model 1 Test result, model 2
Negative/not tested Severe Total Negative Positive Total
Participants (N) 91,041 124 91,165 1802 207 2009
Age at COVID-19 diagnosis 68.1 (61.0-73.2) 69.6 (58.7-75.5) 68.1 (61.0-73.2) 70.5 (62.6-75.3) 64.9 (56.2-73.4) 70.1 (61.6-75.2)
Sex (female) 51,908 (57.0%) 52 (41.9%) 51,960 (57.0%) 949 (52.7%) 103 (49.8%) 1052 (52.4%)
Ethnicity
White European 87,951 (98.4%) 115 (95.8%) 88,066 (98.4%) 1725 (98.0%) 191 (95.0%) 1916 (97.7%)
South Asian 684 (0.8%) 2 (1.7%) 686 (0.8%) 22 (1.3%) 3 (1.5%) 25 (1.3%)
Black/Afro-Caribbean 760 (0.9%) 3 (2.5%) 763 (0.9%) 13 (0.7%) 7 (3.5%) 20 (1.0%)
Townsend deprivation index e2.5 (e3.8 to e0.2) e2.5 (e3.6 to 0.6) e2.5 (e3.8 to e0.2) e2.3 (e3.7 to 0.3) e2.3 (e3.6 to 0.5) e2.3 (e3.7 to 0.3)
Number in household 2.0 (2.0-3.0) 2.0 (2.0-3.0) 2.0 (2.0-3.0) 2.0 (2.0-3.0) 2.0 (2.0-4.0) 2.0 (2.0-3.0)
Fruit and vegetable scoreb 4.3 (3.0-6.0) 4.3 (2.7-6.0) 4.3 (3.0-6.0) 4.3 (3.0-6.0) 4.0 (2.7-6.0) 4.3 (3.0-6.0)
Red meat scorec 1.5 (1.5-2.5) 2.0 (1.5-3.0) 1.5 (1.5-2.5) 1.5 (1.5-2.5) 2.0 (1.5-2.5) 1.5 (1.5-2.5)
Smoking status
Never 52,357 (57.7%) 56 (45.2%) 52,413 (57.6%) 889 (49.4%) 107 (51.2%) 996 (49.7%)
Previous 32,328 (35.6%) 54 (43.5%) 32,382 (35.6%) 754 (41.9%) 79 (38.2%) 833 (41.5%)
Current 6119 (6.7%) 14 (11.3%) 6133 (6.7%) 155 (8.6%) 21 (10.1%) 176 (8.8%)
Alcohol intake frequency 1.5 (0.5-3.5) 1.5 (0.5-3.5) 1.5 (0.5-3.5) 1.5 (0.5-3.5) 1.5 (0.5-3.5) 1.5 (0.5-3.5)
Number of self-reported cancers 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0)
Number of self-reported non-cancer illnesses 1.0 (0.0-2.0) 2.0 (1.0-3.0) 1.0 (0.0-2.0) 2.0 (1.0-3.0) 1.0 (0.0-3.0) 2.0 (1.0-3.0)
Number of treatments/medications taken 1.0 (0.0-3.0) 2.0 (1.0-5.0) 1.0 (0.0-3.0) 2.0 (1.0-4.0) 2.0 (0.0-4.0) 2.0 (1.0-4.0)
Body mass index (kg/m2) 26.0 (23.6-28.9) 27.3 (24.1-31.9) 26.0 (23.6-28.9) 26.8 (24.2-30.2) 27.3 (24.1-31.1) 26.9 (24.2-30.3)
Self-reported sleep duration (h) 7.0 (7.0-8.0) 7.0 (7.0-8.0) 7.0 (7.0-8.0) 7.0 (6.0-8.0) 7.0 (6.0-8.0) 7.0 (6.0-8.0)
Physical activity
Overall physical activity (mg) 27.4 (22.7-33.0) 26.9 (21.3-32.8) 27.4 (22.7-33.0) 25.8 (21.1-31.0) 26.8 (21.9-32.1) 25.9 (21.1-31.1)
Moderate to vigorous PA accumulated in
1-min bouts (min)
42.1 (24.7-65.2) 36.0 (19.4-55.4) 42.0 (24.7-65.2) 34.6 (18.5-55.5) 36.9 (22.2-57.3) 35.0 (18.8-55.9)
Activity and sleep/rest
Activity during waking hours (16 h) (mg) 39.0 (32.2-47.1) 38.2 (29.8-45.9) 39.0 (32.2-47.1) 36.5 (29.8-44.5) 38.1 (30.5-45.5) 36.7 (29.9-44.6)
Amount of movement during sleep (8 h) (mg) 3.8 (3.1-4.9) 4.2 (3.3-5.8) 3.8 (3.1-4.9) 3.9 (3.2-4.9) 4.2 (3.3-5.7) 3.9 (3.2-5.0)
Amount of movement during sleep (6 h) (mg)d 2.8 (2.4-3.2) 3.0 (2.6-3.7) 2.8 (2.4-3.2) 2.8 (2.5-3.3) 3.0 (2.5-3.6) 2.8 (2.5-3.4)
Balance between activity and sleep/rest (%) 142.5 (140.4-144.0) 141.1 (138.0-143.4) 142.5 (140.4-144.0) 141.9 (139.4-143.6) 141.4 (138.6-143.2) 141.8 (139.4-143.6)














































Severity of infection (in UK Biobank), model 1 Test result, model 2
Negative/not tested Severe Total Negative Positive Total
Timing of activity and sleep/rest
Start time of most active 16h per day (hh:mm) 7:05 (6:34-7:37) 7:04 (6:34-7:47) 7:05 (6:34-7:37) 7:07 (6:34-7:38) 7:02 (6:28-7:43) 7:07 (6:34-7:38)
Variability in timing of activity (SD, min) 37.6 (25.0-55.1) 46.4 (31.5-68.4) 37.6 (25.0-55.1) 38.2 (26.4-56.5) 46.7 (31.4-70.8) 38.8 (26.6-57.6)
Start time of least active 8h per day (hh:mm) 23:04 (22:34-23.35) 23:02 (22:28-23:41) 23:04 (22:34-23:35) 23:07 (22:34-23.37) 23:02 (22:28-23:43) 23:05 (22:33-23:37)
Variability in timing of sleep/rest (8 h, SD, min) 37.7 (25.0-55.4) 46.7 (30.4-67.1) 37.6 (25.0-55.1) 38.3 (26.5-56.5) 47.1 (31.0-71.2) 39.1 (26.7-57.7)
Start time of least active 6h per day (hh:mm)d 00:08 (23:34-00:43) 00:08 (23:34-00:58) 00:08 (23:34-00:43) 00:10 (23:34-00:48) 00:07 (23:34-00:53) 00:08 (23:34-00:48)
Variability in timing of sleep/rest (6h, SD, min)d 53.1 (38.0-70.6) 56.6 (40.3-80.8) 53.1 (38.0-70.6) 53.2 (38.9-72.0) 57.2 (40.7-81.8) 53.5 (39.3-72.6)
Mid-point of difference between start of least active 8 h
and most active 16 h (hh:mm)
3:04 (2:34-3:36) 3:02 (2:29-3:41) 3:04 (2:34-3:36) 3:07 (2:34-3:38) 3:02 (2:28-3:43) 3:06 (2:34-3:38)
Variability in sleep/rest mid-point (8 h, SD, min) 37.6 (25.0-55.1) 46.7 (30.6-68.1) 37.6 (25.0-55.1) 38.3 (26.4-56.5) 47.1 (30.6-71.8) 38.8 (26.6-57.6)
Midpoint of difference between start of least active 6 h
and most active 16 h (hh:mm)d
3:36 (3:05-4:09) 3:38 (3:04-4:22) 3:36 (3.05-4:09) 3:38 (3:04-4:13) 3:36 (3:04-4:10) 3:38 (3:04-4:13)
Variability in sleep/rest midpoint (6 h, SD, min)d 39.3 (28.0-54.9) 43.1 (30.1-70.1) 39.3 (28.0-54.9) 40.5 (28.8-55.5) 46.1 (29.8-69.8) 40.9 (28.9-56.5)
aCOVID-19 ¼ coronavirus disease 2019.
bNumber of portions reported per day.
cNumber of portions reported per week.
dTo allow for differences in the duration of sleep, we conducted sensitivity analyses assessing the effects of the average acceleration and timing of the least active 6 h rather than 8 h.
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of activity and rest
B
FIGURE. Association of physical activity, the balance between activity and sleep/rest, and variability in the timing of sleep/rest and activity. (A)
Model 1, severe COVID-19 (UK Biobank cohort as comparator). (B) Model 2, positive test for COVID-19 (negative test result as
comparator). Odds ratios expressed per SD of each variable. Model 2 adjusted for age, sex, ethnicity, TownsendDeprivation Index, number
of people in household, fruit/vegetable consumption, redmeat consumption, smoking status, alcohol intake, number of self-reported cancers
and non-cancer illnesses, and number of treatments/medications.Model 1 adjusted for age, sex, and ethnicity owing to the smaller number of
outcome events. Activity during waking hours and movement during sleep/rest mutually adjusted. “Activity & sleep/rest” and “Variability in
timing of activity and sleep/rest” variables additionally adjusted for sleep duration. “Variability in timing of activity and sleep/rest” additionally
adjusted for overall physical activity. COVID-19¼ coronavirus disease 2019; MVPA¼moderate-to-vigorous physical activity; OR¼ odds
ratio; SD ¼ standard deviation. aSensitivity analyses using the least active 6 hours rather than 8 hours (open circles).
ASSOCIATION OF PHYSICAL ACTIVITY AND REST/SLEEP WITH COVID-193. We did not adjust for BMI in our main ana-
lyses as it is potentially on the causal
pathway from physical activity to COVID-
19 risk. However, we performed sensitivity
analyses for: (1) model 1 further adjusted
for BMI and number of cancer and non-
cancer illnesses (underlying health condi-
tions) and (2) model 2 further adjustedMayo Clin Proc. n January 2021;96(1):156-164 n https://doi.org/10
www.mayoclinicproceedings.orgfor BMI (initial model already adjusted for
underlying health conditions).
4. Although we controlled for deprivation and
household size, it is difficult to determine
risk due to level of exposure. The United
Kingdom was under lockdown during the
period of the study, with people requested
to stay at home. We ran sensitivity analyses.1016/j.mayocp.2020.10.032 161
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162excluding the group likely to have had the
greatest exposure to the virus: health care
workers as they continued working
throughout lockdown (UK Biobank codes
2211001-2216012, N ¼ 1665, of whom 62
were tested [11 positive, 5 severe infec-
tion]). All analyses were performed using
Stata version 16.0 (StataCorp, College Sta-
tion, TX). Statistical significance was set at
the alpha level of 0.05.RESULTS
Data were available for 91,248 individuals, of
whom 2009 had been tested for COVID-19,
207 had a positive test result, and 124 were
classified as having a severe infection. Partic-
ipant characteristics for both models are re-
ported in Table 2.
The results of the regression models are
shown in Figure and Supplemental Table 1
(available online at http://www.mayoclinic
proceedings.org). Results for severe infection
(Figure A) and positive test results (Figure
B) were broadly consistent. Overall physical
activity level and moderate-to-vigorous phys-
ical activity (MVPA) were not significantly
associated with the risk of testing positive for
SARS-CoV-2 or developing severe COVID-
19. A higher amount of movement during
themain sleep/rest period (least active 8 hours;
OR, 1.14-1.26; P< .05) and lower activity dur-
ing waking hours (model 1 only, OR, 0.75
[95% CI, 0.61-0.93]; P ¼ .01) were associated
with increased odds independent of each other
(ie, both were significant in the same model).
Consequently, a worse (lower) balance be-
tween activity and sleep/rest (ie, a smaller
drop in movement during the main sleep/rest
period) was also predictive (OR, 0.71-0.86; P
< .05). Irregular sleeping patterns (greater
variability in the start times of activity during
waking hours, amount of movement during
the main sleep/rest period , and midpoint of
the difference between these times) were
consistently associated with significantly
greater odds (OR, 1.17-1.21; P < .01) across
both models. Results of unadjusted models
were consistent with the adjusted models
(Supplemental Table 1 available online at
http://www.mayoclinicproceedings.org).Mayo Clin Proc. n January 202Sensitivity analyses broadly confirmed
the associations:
1. If the least active 6 hours was as the main
sleep/rest period instead of the least active
8 hours
2. If individuals testing positive in the com-
munity were assumed to be nonsevere
and added to the comparator group for se-
vere infection with SARS-CoV-2
(Supplemental Figure 1, available online
at http://www.mayoclinicproceedings.org)
3. With further adjustment for BMI (models
1 and 2) and cancer and nonecancer ill-
nesses (model 1; Supplemental Figure 2,
available online at http://www.mayoclinic
proceedings.org)
4. When excluding health care workers
(Supplemental Figure 3, available online
at http://www.mayoclinicproceedings.org).DISCUSSION
The balance and variability in timing of activity
and rest were more strongly associated with
the risk of testing positive for SARS-CoV-2 or
incidence of severeCOVID-19 than “standard”
measures of activity (ie, MVPA). This high-
lights the importance of not just physical activ-
ity alone, but also adequate quality sleep/rest.
A distinct activity cycle (better balance be-
tween activity and rest), reflecting a clear
drop in movement during the main sleep/rest
period (one third of the day), was associated
with a lower risk, independent of self-
reported sleep duration. The importance of
quality sleep/rest was further evident in the
positive association between the level ofmove-
ment during sleep/rest (the least active contin-
uous 8 hours) and risk, independent of activity
level during waking hours, in all models.
A better balance between activity and the
dominant sleep/rest period (by 1 SD of the
sample mean) was associated with approxi-
mately 30% lower risk of severe COVID-19.
This more distinct activity cycle could reflect
greater movement during waking hours (16
hours), less movement during the main
sleep/rest period (8 hours), or both. For
example, a 1 SD higher balance between activ-
ity and sleep/rest could reflect the equivalent of
90 minutes of extra-brisk walking12; or lower1;96(1):156-164 n https://doi.org/10.1016/j.mayocp.2020.10.032
www.mayoclinicproceedings.org
ASSOCIATION OF PHYSICAL ACTIVITY AND REST/SLEEP WITH COVID-19movement during the main sleep/rest period
by 1 SD (ie, approximately 2mg) of the sample
mean; or approximately 45 minutes of brisk
walking and lower movement during the
main sleep/rest period by approximately 0.5
SD (ie, approximately 1 mg) of the sample
mean.
Sleep disruption and physical inactivity
can contribute to chronic inflammation13
and to cardiometabolic disease, which in
turn is associated with an increased risk of
COVID-19.1 Furthermore, as COVID-19 is
an acute inflammatory disease, it might exac-
erbate existing chronic inflammation associ-
ated with poor activity and rest behaviors or
existing cardiometabolic disease. Alongside
other risk factors (eg, psychological stress
and genetic predisposition), the virus might
be associated with a “cytokine storm”13
contributing to the observed increased risk
of severe COVID-19.
The consistently 1.2-fold higher risk of
COVID-19 per approximately 40-minute in-
crease in variability in timing of sleep/rest,
indicative of irregular sleeping patterns,
further supports the finding that risk factors
for cardiovascular and cardiometabolic dis-
ease4,5 are also risk factors for COVID-19.2,3
Limitations
Characteristics of participants, including
accelerometer data, were measured before
the current pandemic. Although the analyses
were controlled for deprivation and house-
hold size, it was not possible to determine
level of exposure to infection; however, re-
sults were robust when excluding the group
likely to have had the highest level of expo-
sure to the virus, health care workers. The
definition of severe COVID-19 was a positive
test from a hospital inpatient, consistent with
the definition proposed by the researchers
who developed the linkage method8; howev-
er, actual disease severity cannot be
confirmed from the linkage data available at
the time of analysis. Furthermore, partici-
pants in UK Biobank might not be represen-
tative of the wider population and testing in
the UK has not been universal, making ana-
lyses vulnerable to bias. However, partici-
pants might not need to be representativeMayo Clin Proc. n January 2021;96(1):156-164 n https://doi.org/10
www.mayoclinicproceedings.orgwhen estimating relative risk factor associa-
tions, as empirically demonstrated for UK
Biobank.14 As such, our results point to the
potential importance of rest and physical ac-
tivity as predictive of later risk of COVID-
19 infection and should be confirmed with
current databases from other populations.CONCLUSION
This report provides evidence of an associa-
tion between markers of sleep/rest and phys-
ical activity and the risk or severity of
COVID-19 infection. Public health studies
could incorporate such measures to better
identify and protect individuals at high risk
of COVID-19 or cardiometabolic disease.ACKNOWLEDGMENTS
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